These experiments supported our novel finding that key CME pathway components—clathrin, RAB5 and RAB11- are OGT targets, though no quantitative readout regarding a change in O-GlcNAcylation status between normal pregnancy and diabetes could be made due to the limited sensitivity of this method for detecting subtle changes in the level of O-GlcNAcylation, especially when multiple sites, each of which could be more or less O-GlcNAcylated, are present. The gene discussed is RAB5A; the disease is diabetes mellitus.